This article summarized the latest R&D progress of Paroxetine Mesylate, mechanism of action for Paroxetine Mesylate, and the drug target R&D trends for Paroxetine Mesylate.

ACE inhibitors are a class of drugs that work by relaxing blood vessels, inhibiting the production of the vasoconstrictor substance Angiotensin II. This results in lower blood pressure, reduced cardiac load, and decreased risk of hypertension.

A Contrast agent, also known as a contrast medium, is a specific substance that is introduced into the human body for the purpose of medical imaging – it is used to alter the contrast of images of parts of the body.

Kodiak Sciences recently revealed that its Phase III GLOW study of tarcocimab tedromer, a 5 mg ABC therapy for moderate to severe NPDR, met its primary one-year endpoint.

This article summarized the latest R&D progress of Pegvisomant, the Mechanism of Action for Pegvisomant, and the drug target R&D trends for Pegvisomant.

4-1BB (also known as CD137 or TNFRSF9) was first discovered in 1989 and is a critical co-stimulation receptor on T cells and other immune cells.

This article summarized the latest R&D progress of Penicillin G Procaine, the Mechanism of Action for Penicillin G Procaine, and the drug target R&D trends for Penicillin G Procaine.

Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.

This article summarized the latest R&D progress of Pentobarbital Sodium, the Mechanism of Action for Pentobarbital Sodium, and the drug target R&D trends for Pentobarbital Sodium.

The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.

This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).